Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialPubMed

Differences in adipose-derived stem cells from rats with various health statuses and their effects in diabetic rats with erectile dysfunction.

Liu GC., Zheng L., Wei LT., Liu ZY., Jiang H., Jiang T.

Randomized Controlled Trial on Systemic / IV, published in Asian J Androl (2026) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Asian J Androl (2026)
Country
China
Reported sample size
—
Source database
PubMed
PMID
41699953
DOI
10.4103/aja202594

Abstract (original English)

It is essential to use high-quality adipose-derived stem cells (ADSCs) for clinical applications. The functional characteristics of ADSCs differ in the presence of various health conditions. Specifically, recent studies of the therapeutic effects of ADSCs from individuals with diabetes and no erectile dysfunction (NED-ADSCs), ADSCs from those with diabetes and erectile dysfunction (ED-ADSCs), and normal ADSCs have generated conflicting results. Therefore, we aimed to provide evidence for the clinical utility of ADSCs. Diabetes mellitus (DM) was induced in rats by the intraperitoneal injection of streptozotocin (STZ; 40 mg kg-1) following 4 weeks of high-fat diet feeding. After 12 weeks, erectile dysfunction was confirmed using the apomorphine (80 µg kg-1) test, and those with diabetes mellitus-related erectile dysfunction (DMED) were randomly assigned to treatment groups. Each group was administered 1 × 106 allogeneic ADSCs by injection into the corpus cavernosum; then, erectile function and penile histology were evaluated 28 days later. Of the three ADSCs types injected, normal ADSCs exhibited the strongest proliferation and differentiation capabilities. Following ADSCs treatment, there was an increase in smooth muscle cell number and a higher muscle-to-collagen fiber ratio. The expression of neuronal nitric oxide synthase (nNOS) in the dorsal nerve significantly increased. In

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research